PDCD1 and hepatocellular carcinoma: To our knowledge, this is the first study to evaluate the incidence of HBVr in HBV-related HCC patients with first-line antivirals who were receiving anti-PD-1 monotherapy or combined anti-PD-1 plus angiogenesis inhibitors.